178 related articles for article (PubMed ID: 28185649)
1. Treatment by rituximab on six Grave's ophthalmopathies resistant to corticosteroids.
Précausta F; Arsène S; Renoult-Pierre P; Laure B; Crinière L; Pisella PJ
Ann Endocrinol (Paris); 2017 Feb; 78(1):20-26. PubMed ID: 28185649
[TBL] [Abstract][Full Text] [Related]
2. [Treatment of Grave's ophthalmopathy with high doses of corticosteroids].
Cirić J; Zarković M; Stojanović M; Pepenezić Z; Randjelović G; Gligorović M; Trbojević B; Drezgić M; Nesović M
Srp Arh Celok Lek; 2000; 128(5-6):179-83. PubMed ID: 11089418
[TBL] [Abstract][Full Text] [Related]
3. Use of Rituximab After Orbital Decompression Surgery in Two Grave's Ophthalmopathy Patients Progressing to Optic Neuropathy.
Zhang B; Li Y; Xu W; Peng B; Yuan G
Front Endocrinol (Lausanne); 2020; 11():583565. PubMed ID: 33193097
[TBL] [Abstract][Full Text] [Related]
4. Advances in treatment of active, moderate-to-severe Graves' ophthalmopathy.
Wiersinga WM
Lancet Diabetes Endocrinol; 2017 Feb; 5(2):134-142. PubMed ID: 27346786
[TBL] [Abstract][Full Text] [Related]
5. Combined orbital irradiation and systemic steroids compared with systemic steroids alone in the management of moderate-to-severe Graves' ophthalmopathy: a preliminary study.
Ng CM; Yuen HK; Choi KL; Chan MK; Yuen KT; Ng YW; Tiu SC
Hong Kong Med J; 2005 Oct; 11(5):322-30. PubMed ID: 16219950
[TBL] [Abstract][Full Text] [Related]
6. Efficacy Profile and Safety of Very Low-Dose Rituximab in Patients with Graves' Orbitopathy.
Vannucchi G; Campi I; Covelli D; Currò N; Lazzaroni E; Palomba A; Soranna D; Zambon A; Fugazzola L; Muller I; Guastella C; Salvi M
Thyroid; 2021 May; 31(5):821-828. PubMed ID: 33234032
[No Abstract] [Full Text] [Related]
7. Therapeutic outcomes of high-dose intravenous steroids in the treatment of dysthyroid optic neuropathy.
Currò N; Covelli D; Vannucchi G; Campi I; Pirola G; Simonetta S; Dazzi D; Guastella C; Pignataro L; Beck-Peccoz P; Ratiglia R; Salvi M
Thyroid; 2014 May; 24(5):897-905. PubMed ID: 24417307
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the patients with Grave's ophthalmopathy after the corticosteroids treatment.
Petrović MJ; Sarenac T; Srećković S; Petrović M; Vulović D; Janićijević K
Vojnosanit Pregl; 2012 Mar; 69(3):249-52. PubMed ID: 22624411
[TBL] [Abstract][Full Text] [Related]
9. Reduced risk of compressive optic neuropathy using orbital radiotherapy in patients with active thyroid eye disease.
Shams PN; Ma R; Pickles T; Rootman J; Dolman PJ
Am J Ophthalmol; 2014 Jun; 157(6):1299-305. PubMed ID: 24582992
[TBL] [Abstract][Full Text] [Related]
10. Clinical and immunological changes in patients with active moderate-to-severe Graves' orbitopathy treated with very low-dose rituximab.
Karasek D; Cibickova L; Karhanova M; Kalitova J; Schovanek J; Frysak Z
Endokrynol Pol; 2017; 68(5):498-504. PubMed ID: 28660988
[TBL] [Abstract][Full Text] [Related]
11. Transcaruncular orbital decompression: an alternate procedure for Graves ophthalmopathy with compressive optic neuropathy.
Liao SL; Chang TC; Lin LL
Am J Ophthalmol; 2006 May; 141(5):810-818. PubMed ID: 16527228
[TBL] [Abstract][Full Text] [Related]
12. [Management of Graves' ophthalmopathy].
Schalin-Jäntti C
Duodecim; 2010; 126(20):2431-7. PubMed ID: 21125757
[TBL] [Abstract][Full Text] [Related]
13. Treatment of Graves' disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study.
Salvi M; Vannucchi G; Campi I; Currò N; Dazzi D; Simonetta S; Bonara P; Rossi S; Sina C; Guastella C; Ratiglia R; Beck-Peccoz P
Eur J Endocrinol; 2007 Jan; 156(1):33-40. PubMed ID: 17218723
[TBL] [Abstract][Full Text] [Related]
14. Low-Dose Rituximab for Active Moderate to Severe Graves' Orbitopathy Resistant to Conventional Treatment.
Du Pasquier-Fediaevsky L; Andrei S; Berche M; Leenhardt L; Héron E; Rivière S
Ocul Immunol Inflamm; 2019; 27(5):844-850. PubMed ID: 29652204
[No Abstract] [Full Text] [Related]
15. The effects of Rituximab on Graves'orbitopathy: A retrospective study of 14 patients.
Eid L; Coste-Verdier V; Longueville E; Ribeiro E; Nicolescu-Catargi B; Korobelnik JF
Eur J Ophthalmol; 2020 Sep; 30(5):1008-1013. PubMed ID: 31025590
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Rituximab for the Treatment of Graves' Orbitopathy: A Meta-analysis of Randomized Controlled Trials.
Shen WC; Lee CH; Loh EW; Hsieh AT; Chen L; Tam KW
Pharmacotherapy; 2018 May; 38(5):503-510. PubMed ID: 29601105
[TBL] [Abstract][Full Text] [Related]
17. Complete recovery of visual acuity as the main goal of treatment in patients with dysthyroid optic neuropathy.
Miśkiewicz P; Rutkowska B; Jabłońska A; Krzeski A; Trautsolt-Jeziorska K; Kęcik D; Milczarek-Banach J; Pirko-Kotela K; Samsel A; Bednarczuk T
Endokrynol Pol; 2016; 67(2):166-73. PubMed ID: 26884288
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of rituximab in patients with Graves' orbitopathy: a retrospective multicenter nationwide study.
Deltour JB; d'Assigny Flamen M; Ladsous M; Giovansili L; Cariou B; Caron P; Drui D; Lebranchu P
Graefes Arch Clin Exp Ophthalmol; 2020 Sep; 258(9):2013-2021. PubMed ID: 32405700
[TBL] [Abstract][Full Text] [Related]
19. Enduring remission of active and sight-threatening Graves' orbitopathy with rituximab: report of two cases.
Adamidou F; Anagnostis P; Boboridis K; Manani C; Georgiou T; Veneti S; Kita M
Endocr J; 2018 Sep; 65(9):963-967. PubMed ID: 29937466
[TBL] [Abstract][Full Text] [Related]
20. Optimization of the treatment of moderate to severe and active thyroid orbitopathy considering the recommendations of the European Group on Graves' Orbitopathy (EUGOGO) [Optymalizacja leczenia umiarkowanej do ciężkiej i aktywnej orbitopatii tarczycowej z uwzględnieniem zaleceń European Group on Graves' Orbitopathy (EUGOGO)].
Nowak M; Marek B; Kos-Kudła B; Siemińska L; Londzin-Olesik M; Głogowska-Szeląg J; Nowak W; Kajdaniuk D
Endokrynol Pol; 2022; 73(4):756-777. PubMed ID: 36059167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]